Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2018-06-11 Capital/Financing Update
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes a material definitive agreement amendment related to a senior secured convertible note, including conversion of debt to equity shares and waiver of rights. It also details unregistered sales of equity securities. The document includes an exhibit of the amendment agreement. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The focus is on a financing-related amendment and equity issuance. Therefore, this fits best under Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information about financing activities, not just an announcement or certification, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2018-06-11 English
FORM 4
Director's Dealing
2018-06-01 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 24, 2018, reporting on the results of the 2018 Annual Meeting of Stockholders of KemPharm, Inc. It details the submission of matters to a vote of security holders, including election of directors and ratification of the independent auditor. The content focuses on official voting results from the shareholder meeting. The document length is 3991 characters, which is relatively short and consistent with a voting results announcement rather than a full annual report or other detailed filings. The key section is 'Item 5.07 Submission of Matters to a Vote of Security Holders,' which matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). Therefore, the appropriate classification is DVA with high confidence.
2018-05-24 English
FORM 4
Director's Dealing
2018-05-24 English
FORM 4
Director's Dealing
2018-05-24 English
FORM 4
Director's Dealing
2018-05-24 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.